About Blue Rock Therapeutics
Blue Rock Therapeutics is a Healthcare company based in Boston (United States) founded in 2016, and was acquired by Leaps by Bayer in August 2019. Stem cell therapies are developed for cardiovascular and neurological diseases. Blue Rock Therapeutics has raised $225 million across 1 funding round from investors including Versant Ventures and Leaps by Bayer. The company has 138 employees. Its website bluerocktx.com draws about 19 thousand monthly visits. Blue Rock Therapeutics offers products and services including bemdaneprocel and OpCT-001. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Pluripotent Stem Cells. Its legal entity is BLUEROCK THERAPEUTICS LP. Its competitors include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed competitors has raised funding.
Company details
Blue Rock Therapeutics was founded in 2016 and is based in Boston, United States. Operations center on the biotechnology sector, where stem cell therapeutics are developed to address cardiovascular and neurological conditions. The lead program targets heart muscle regeneration for patients recovering from heart attacks or managing chronic heart failure. Additional efforts extend to broader neurological applications through stem cell-based treatments.
- Headquarters Boston, United States
- Employees 138
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website bluerocktx.com
- Social LinkedIn X
- Acquired by Leaps by Bayer (Aug 2019)
- Legal Name Bluerock Therapeutics Lp
- Total Equity Funding$225M (USD)
in 1 rounds
- Latest Funding Round$225M (USD), Series A
Dec 2016
- InvestorsVersant Ventures
& 1 more
- Employee Count138
- Acquired byLeaps by Bayer
(Aug 2019)
Products & Services of Blue Rock Therapeutics
Blue Rock Therapeutics offers a comprehensive portfolio of products and services, including bemdaneprocel and OpCT-001.
Investigational therapy for treating Parkinson's disease in clinical trials.
Therapy for primary photoreceptor diseases through iPSC-derived cells.
Funding Insights of Blue Rock Therapeutics
Blue Rock Therapeutics has successfully raised a total of $225M through 1 strategic funding round. The most recent funding activity was a Series A round of $225 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $225M
- Total Rounds 1
- Last Round Series A — $225M
- First Round $225M
(Dec 2016)
- Investors Count 2
All 1 funding rounds of Blue Rock Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $225M | Series A | – | Versant Ventures, Leaps by Bayer | – |
2 investors in total: 2 institutional.
Investors in Blue Rock Therapeutics
Blue Rock Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Versant Ventures and Leaps by Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany |
Investor details for Blue Rock Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Blue Rock Therapeutics
210 people are tracked at Blue Rock Therapeutics (80 in leadership, 8 in board & advisors, 122 in team); the tracked headcount is 138.
| Name | Role | Group |
|---|---|---|
Ed Trzaska | Senior Director/head, Portfolio Analytics & Insights | Leadership |
Robin B. | Vice President, Business And Manufacturing Solutions | Leadership |
Maria Nason | Associate Director, Toronto Site Quality Assurance | Leadership |
Rucheer Shah Cqe | Associate Director, Quality Assurance | Leadership |
Michael van Winden | Sr. Director, External Manufacturing & Procurement | Leadership |
Sandra Milasta | Director | Leadership |
Ronnie Lum | Associate Director - Assay Development | Leadership |
Anne Koehler | Director, Business Process Management | Leadership |
Michael Penn | Vice President, Intellectual Property | Leadership |
Gabriel Belfort | Senior Vice President, Bemdaneprocel Product Lead | Leadership |
Lucia Wille | Sr. Director, Clinical Pharmacology And Biodistribution | Leadership |
Alison Clain | Associate Director, Data Management | Leadership |
Maya Srinivas | Senior Director | Leadership |
Jennifer Santangelo | Manager, Executive Business Partner | Leadership |
David Dilworth | Associate Director | Leadership |
Juliana Ya-Chu Hsu | Associate Director | Leadership |
Brenda W. | Director, Portfolio Strategy & New Product Planning | Leadership |
Richard Reineke | Vice President Operations | Leadership |
Michael Rivera | Associate Director, Program Management | Leadership |
Stephanie Fisher | Associate Director/ Principal Scientist, Process Development | Leadership |
190 more people are available in the full profile.
Complete people profiles for Blue Rock Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Blue Rock Therapeutics
3 dated milestones of Blue Rock Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Blue Rock Therapeutics is founded.
- Funding First funding round of $225.0M.
- Exit Acquired by Leaps by Bayer.
Competitors of Blue Rock Therapeutics
Blue Rock Therapeutics has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of Blue Rock Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Blue Rock Therapeutics
The website of Blue Rock Therapeutics (bluerocktx.com) receives about 19.4K visits a month and ranks #2,205,693 among all websites worldwide, #2,998 in Biotechnology and Pharmaceuticals.
- Monthly visits19.4K
▲ 79.8% vs previous month
- Unique visitors5K
per month
- Global rank#2,205,693
among all websites
- Category rank#2,998
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.6
- Average visit21 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Blue Rock Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| askbio.com | 100% | 14.3K | #2,158,975 | View details | |
| bayer.com | 93% | 1.1M | #52,188 | View details | |
parkinsonsnewstoday.com | parkinsonsnewstoday.com | 56% | #376,359 | – | |
| neurologylive.com | 56% | 170.9K | #299,267 | View details | |
parkinson.ca | parkinson.ca | 56% | #971,429 | – |
Top companies in Cell Therapy
3 companies that operate in the same segment as Blue Rock Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Blue Rock Therapeutics
Complete news archive for Blue Rock Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blue Rock Therapeutics
Blue Rock Therapeutics was founded in 2016.
Blue Rock Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Blue Rock Therapeutics is a funded company, having raised a total of $225M across 1 funding round to date. The company's 1st funding round was a Series A of $225M, raised on Dec 2016.
Blue Rock Therapeutics has 138 employees.
Blue Rock Therapeutics was founded in 2016 and is based in Boston, United States. Operations center on the biotechnology sector, where stem cell therapeutics are developed to address cardiovascular and neurological conditions. The lead program targets heart muscle regeneration for patients recovering from heart attacks or managing chronic heart failure. Additional efforts extend to broader neurological applications through stem cell-based treatments.
Blue Rock Therapeutics's top competitors include Roivant Sciences, Lilly and Gilead.
Blue Rock Therapeutics offers bemdaneprocel and OpCT-001.
Blue Rock Therapeutics has 2 investors. Key investors include Versant Ventures, and Leaps by Bayer.
Blue Rock Therapeutics operates through Bluerock Therapeutics Lp.
Yes. Blue Rock Therapeutics was acquired by Leaps by Bayer in August 2019.